The European Medicines Agency recommended 12 new medicines and eight label expansions, boosting U.S. drugmakers Johnson & Johnson and Gilead.
The European Medicines Agency’s expert panel endorsed 12 new medicines and eight label expansions for approval this week. Among the recipients were products from U.S. pharmaceutical companies Johnson & Johnson (JNJ) and Gilead Sciences (GILD).
The recommendations follow the agency’s standard review process, which evaluates clinical data before potential final approval by the European Commission. This week’s endorsements cover a range of therapeutic areas, though specific drug details were not disclosed.
The move signals regulatory progress for drugmakers targeting the EU market, potentially accelerating commercial launches and revenue growth for approved treatments.